Vital sign measurements for Diffuse Large B-cell Lymphoma

Phase-Based Progress Estimates
Diffuse Large B-cell Lymphoma+1 MoreVital sign measurements - Procedure
18 - 75
All Sexes
What conditions do you have?

Study Summary

This trial will test if a new cancer treatment can be given safely to patients outside of a hospital.

Eligible Conditions
  • Diffuse Large B-cell Lymphoma
  • Non-Hodgkin's Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: at 30 days

Approximately 30 days
Calculate cost of administering YESCARTA in the out-patient setting
Count of risk factors that preclude out-patient administration of YESCARTA
Measure cumulative steroid exposure
Measure effectiveness of close monitoring of participants in the out-patient setting
Approximately 6 weeks
Feasibility of treating participants with YESCARTA in the out patient setting
at 30 days
Measure time to specific interventions post infusion

Trial Safety

Trial Design

1 Treatment Group

YESCARTA in the Outpatient Setting
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Vital sign measurements · No Placebo Group · N/A

YESCARTA in the Outpatient SettingExperimental Group · 5 Interventions: Vital sign measurements, Telemedicine Visit, Visit from Home Health Nurse, Out-Patient Clinic Visit, Blood pressure and pulse oximeter · Intervention Types: Procedure, Procedure, Procedure, Procedure, Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
Telemedicine Visit

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 30 days

Who is running the clinical trial?

Vanderbilt-Ingram Cancer CenterLead Sponsor
202 Previous Clinical Trials
65,481 Total Patients Enrolled
Kite, A Gilead CompanyIndustry Sponsor
30 Previous Clinical Trials
3,129 Total Patients Enrolled
Olalekan Oluwole, MDPrincipal InvestigatorVanderbilt-Ingram Cancer Center

Eligibility Criteria

Age 18 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of CLL/SLL and are eligible for leukapheresis.
You have two lines of therapy, one of which includes an anthracycline and a CD20-targeted therapy, and you have failed both of them.
Creatinine clearance ≥ 60 mL/min/1.73 m2.
You have a cardiac ejection fraction of 50% or more.